ALNY:NSD-Alnylam Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 281.49

Change

-3.20 (-1.12)%

Market Cap

USD 36.83B

Volume

0.97M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Address: 675 West Kendall Street, Cambridge, MA, United States, 02142

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.72 (+1.00%)

USD 121.32B
REGN Regeneron Pharmaceuticals Inc

-4.54 (-0.49%)

USD 103.77B
ARGX argenx NV ADR

-1.17 (-0.21%)

USD 33.21B
BGNE BeiGene Ltd

-10.54 (-4.87%)

USD 24.57B
MRNA Moderna Inc

-0.50 (-0.91%)

USD 20.52B
RPRX Royalty Pharma Plc

+0.04 (+0.15%)

USD 16.47B
UTHR United Therapeutics Corporatio..

+8.60 (+2.44%)

USD 15.69B
SMMT Summit Therapeutics PLC

-3.18 (-14.57%)

USD 15.13B
PCVX Vaxcyte Inc

+0.55 (+0.52%)

USD 13.95B
BMRN Biomarin Pharmaceutical Inc

-3.23 (-4.62%)

USD 13.32B

ETFs Containing ALNY

GNOG:LSE Global X Genomics & Biote.. 7.71 % 0.00 %

+0.02 (+0.42%)

USD 5.77M
GN0M:XETRA Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 6.79 % 0.00 %

N/A

USD 5.93M
MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.76 % 0.00 %

-0.06 (0.42%)

N/A
CURG:LSE VanEck Genomics and Healt.. 5.47 % 0.00 %

+0.06 (+0.42%)

USD 5.12M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

-0.15 (0.42%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 3.73 % 0.00 %

-0.11 (0.42%)

USD 0.04B
BBH VanEck Biotech ETF 3.71 % 0.35 %

-0.05 (0.42%)

USD 0.45B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.62 % 0.00 %

+0.15 (+0.42%)

USD 0.04B
BBP Virtus LifeSci Biotech Pr.. 2.58 % 0.79 %

-0.56 (0.42%)

USD 0.02B
BIB ProShares Ultra Nasdaq Bi.. 2.57 % 0.95 %

-0.61 (0.42%)

USD 0.09B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.48 % 0.00 %

-8.50 (0.42%)

USD 0.05B
ZUH:CA BMO Equal Weight US Healt.. 2.30 % 0.39 %

+0.10 (+0.42%)

CAD 0.26B
EQQJ:XETRA Invesco NASDAQ Next Gener.. 2.29 % 0.00 %

-0.31 (0.42%)

USD 0.05B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

-0.01 (0.42%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

N/A

N/A
TMFX Motley Fool Next Index ET.. 2.06 % 0.00 %

-0.07 (0.42%)

USD 0.03B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

-0.23 (0.42%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

-2.65 (0.42%)

N/A
THNZ:XETRA L&G Global Thematic ESG E.. 0.87 % 0.00 %

-0.08 (0.42%)

N/A
IUSZ:SW iShares Edge MSCI USA Siz.. 0.52 % 0.00 %

N/A

N/A
IWSZ:SW iShares Edge MSCI World S.. 0.21 % 0.00 %

N/A

USD 0.28B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.42 (0.42%)

N/A
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

+0.30 (+0.42%)

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

+0.33 (+0.42%)

USD 1.18B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.01 (0.42%)

USD 7.39B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.42 (0.42%)

USD 0.91B
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.05 (+0.42%)

CAD 0.01B
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.02 (0.42%)

USD 0.08B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.02 (+0.42%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+0.42%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (0.42%)

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

-0.08 (0.42%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.02 (0.42%)

USD 0.52B
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.12 (0.42%)

USD 0.02B
IS3T:XETRA iShares MSCI World Size F.. 0.00 % 0.00 %

-0.19 (0.42%)

USD 0.24B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
BMED BlackRock Future Health E.. 0.00 % 0.00 %

-0.02 (0.42%)

USD 4.17M
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

-0.15 (0.42%)

USD 0.68B
QQQN VictoryShares Nasdaq Next.. 0.00 % 0.00 %

N/A

USD 0.02B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

+19.60 (+0.42%)

USD 8.17M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

+0.27 (+0.42%)

USD 8.17M
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.09 (+0.42%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.06% 54% F 76% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.06% 54% F 76% C+
Trailing 12 Months  
Capital Gain 79.29% 54% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 79.29% 54% F 76% C+
Trailing 5 Years  
Capital Gain 209.30% 68% D+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 209.30% 68% D+ 84% B
Average Annual (5 Year Horizon)  
Capital Gain 14.00% 62% D 68% D+
Dividend Return 14.00% 62% D 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.91% 90% A- 66% D+
Risk Adjusted Return 52.02% 95% A 79% B-
Market Capitalization 36.83B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.